非小细胞肺癌术后评估及中医药治疗研究进展

Research Progress of Non-Small Cell Lung Cancer Postoperative Evaluation and Traditional Chinese Medicine Treatment

癌症是如今世界范围内的一大难题,据2019年统计,肺癌发病率在癌症发病率中均位居第二,死亡率在癌症相关死亡中位居第一,其中非小细胞肺癌占肺癌发病率的绝大多数,早期非小细胞肺癌以手术治疗为主要治疗措施,然而预防术后肿瘤及减轻术后化疗等带来的副反应仍是现今待解决的一大难题。早在19世纪70年代,国医大师刘嘉湘就提出了“扶正抗癌”的治疗思想,大量研究证明中医药治疗在提高肿瘤患者生存率、降低复发转移、改善生存质量、辅助治疗中降低西药毒副反应等方面均有显著疗效,本文将就非小细胞肺癌术后评估及中医药治疗研究进展进行整理总结。

Cancer is a worldwide problem nowadays. According to the 2019 statistics, the incidence of lung cancer is the second highest among all cancers, while the mortality rate is the first among cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for the vast majority of lung cancer incidence whose main treatment is surgical excision. However, it remains a difficult problem to prevent postoperative tumor and reduce the side effects of postoperative chemotherapy. In the 1870s, Liu Jiaxiang, a Chinese medicine master, put forward the idea of “Treating Cancer by Strengthening Vital Qi”. A large number of studies have proved that traditional Chinese medicine therapy has significant effects in improving the survival rate of tumor patients, reducing recurrence and metastasis, improving the quality of life, and reducing toxic and side effects of western medicine in adjuvant therapy. This paper will summarize the research progress of the postoperative evaluation of NSCLC and traditional Chinese medicine (TCM) treatment.